BioStock: Intense Q4 leads Annexin into interesting 2023

Intense and significant – that is how Annexin Pharmaceutical’s CEO Anders Haegerstrand describes the year 2022. Standing out is the company’s big leap forward with drug candidate ANXV within the serious vascular disease retinal vein occlusion. The year ended with the company also taking its first step into the cancer field, which opens up another exciting year.

Read the article about Annexin Pharmaceuticals at biostock.se:

https://www.biostock.se/en/2023/02/intense-q4-leads-annexin-into-interesting-2023/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/